UDCA in the Treatment of COVID-19 Infection and Its Clinical Prognosis in Patients With Autoimmune Liver Disease
NCT05812612
·
clinicaltrials.gov ↗
UNKNOWN
Status
2000
Enrollment
OTHER
Sponsor class
Conditions
COVID-19 Infection
Interventions
DRUG:
ursodeoxycholic acid
Sponsor
Beijing Ditan Hospital